Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children
|ClinicalTrials.gov Identifier: NCT00173563|
Recruitment Status : Unknown
Verified August 2005 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : September 15, 2005
Last Update Posted : December 3, 2007
Severe acute respiratory syndrome (SARS) is a new emerging infectious disease. Its pathogen is a newly discovered coronavirus (SARS-CoV). The clinical course can be classified to 3 stages: viral replication phase, hyperimmune reactive phase, and pulmonary destruction phase. Human monocyte plays a critical role in the initiation of immune response in defending the intracellular pathogens (eg viruses). Monocytes can engulf viruses and present the viral antigens in the major histocompatibility (MHC) molecule to the cell surface to initiate T lymphocyte response. Monocytes also secrete various cytokines to modulate immune response. SARS-CoV is a mutant of animal virus to cause human disease and is able to cause unusual severe respiratory illness. It is suggested the unusual severe disease is due to the intense immune reaction.
The investigators will harvest human monocytes from healthy adult and children blood donors. Monocytes would be cultured and infected by SARS-CoV. The change of viral load is monitored after infection. Cytokines secreted by monocytes after infection are also measured. The difference of monocyte cytokine secretion is compared between adults and children. The study is to verify the SARS-CoV infectivity of human monocytes and prove the unusual severity caused by SARS-CoV is related to viral-induced dysregulation of cytokine responses. The results may also clarify why adults tend to have a more severe illness compared with children.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||10 participants|
|Official Title:||Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children|
|Study Start Date :||January 2005|
|Estimated Study Completion Date :||September 2005|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00173563
|National Taiwan University Hospital||Recruiting|
|Taipei, Taiwan, 100|
|Contact: Luan-Yin Chang, MD, PhD 886-2-23123456 ext 3245 Ly7077@tpts6.seed.net.tw|
|Contact: Pei-Lan Shao, MD 886-2-23123456 ext 2394 email@example.com|
|Principal Investigator:||Luan-Yin Chang, MD, PhD||Department of pediatrics, National Taiwan University Hospital|